Skip to main content
. 2020 Dec 21;10(2):615–625. doi: 10.1002/cam4.3638

FIGURE 2.

FIGURE 2

Progression‐free survival (PFS) and overall survival (OS) with respect to grade 3 or 4 neutropenia and hypertension within the first four cycles of treatment in mCRC patients who were treated with second‐line chemotherapy. This figure shows PFS (A, C) and OS (B, D) in patients with grade 3 or 4 neutropenia and hypertension within the first four cycles of treatment compared to those without grade 3 or 4 neutropenia and hypertension